Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy Read more about Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy
Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study Read more about Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study
Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update Read more about Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update
OncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics’ Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy Read more about OncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics’ Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference Read more about Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020 Read more about Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020
Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation Read more about Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation
Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders Read more about Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders
Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020 Read more about Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020
Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today Read more about Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today